Download PDF
Thromb Haemost 1994; 72(02): 326-327
DOI: 10.1055/s-0038-1648863
Letter to the Editor
Schattauer GmbH Stuttgart

Platelet Intracellular Calcium Is not Modified by Subcutaneous Administration of Erythropoietin

Claudia Lo Cascio
Università di Verona, Istituto di Chimica e Microscopia Clinica, Verona, Italia
,
Patrizia Guzzo
Università di Verona, Istituto di Chimica e Microscopia Clinica, Verona, Italia
,
Carmelo Loschiavo
1   Istituto di Nefrologia Medica, Verona, Italia
,
Franco Manzato
Università di Verona, Istituto di Chimica e Microscopia Clinica, Verona, Italia
,
Clara Lechi
Università di Verona, Istituto di Chimica e Microscopia Clinica, Verona, Italia
› Author Affiliations
Further Information

Publication History

Received 14 September 1993

Accepted after revision 31 March 1994

Publication Date:
21 August 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Van Geet C, Van Damme-Lombaerts R, Vanrusselt M, de Mol A, Proes-mans W, Vermylen J. Recombinant human erythropoietin increases blood pressure, platelets aggregability and platelet free calcium mobilisation in uremic children: a possible link?. Thromb Haemost 1990; 64: 7-10
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H. Effect of recombinant human erythropietin (r-HuEpo) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991; 36: 252-257
    PubMedGoogle Scholar
  • 3 Zirkman DM, Zeigler ZR, Fraley DS, Bruns FJ, Adler S. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin. Am J Kidney Dis 1993; 21: 31-37
    PubMedGoogle Scholar
  • 4 Stenver D, Nielsen B, Jeppesen LL, Dalsgaard-Nielsen J, Winther K, Haedersdal C, Mehlsen J. Erythropoietin and fibrinolysiseffects on platelet activity. Lancet 1993; 341: 495-496
    PubMedGoogle Scholar
  • 5 Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1998; 1: 97-100
    PubMedGoogle Scholar
  • 6 Grynkyewicz G, Poenie M, Tsien RY. A new generation of Ca++ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
    CrossrefPubMedGoogle Scholar
  • 7 Raine AEG, Roger SD. Effect of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18: 76-83
    PubMedGoogle Scholar
  • 8 Huang C, Davis G, Johns EJ. Role of haematocrit in mediating the actions of chronic erythropoietin treatment on blood pressure and renal haemodina-mics in the rat. Clin Sci 1993; 85: 717-724
    CrossrefPubMedGoogle Scholar
  • 9 Lechi C, Minuz P, Guzzo P, Paluani F, Arosio E, Gandini G, Lechi A, Zatti M. Effect of nifedipine on platelet intracellular calcium and ADP-induced aggregation and in vivo prostanoid metabolism. High Blood Pressure 1993; 2: 213-220
    PubMedGoogle Scholar
  • 10 Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-278
    CrossrefPubMedGoogle Scholar